Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$29.94
-0.09-0.30%
At close: -
$29.94
0.000.00%
After Hours: Jun 20, 4:00 PM EDT
Comments
Loading...
LENZ Therapeutics Analyst Ratings and Price Targets | NASDAQ:LENZ | Benzinga
LENZ Therapeutics Inc has a consensus price target of $40.17 based on the ratings of 7 analysts. The high is $51 issued by Piper Sandler on April 14, 2025. The low is $32 issued by Leerink Partners on April 15, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler on May 8, 2025, April 16, 2025, and April 14, 2025, respectively. With an average price target of $42.33 between HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler, there's an implied 41.39% upside for LENZ Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Citigroup
Raymond James
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for LENZ Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2025 | Buy Now | 26.92% | HC Wainwright & Co. | Matthew Caufield38% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2025 | Buy Now | 26.92% | HC Wainwright & Co. | Matthew Caufield38% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 04/14/2025 | Buy Now | 70.34% | Piper Sandler | Biren Amin40% | $38 → $51 | Maintains | Overweight | Get Alert |
| 03/20/2025 | Buy Now | 56.98% | Citigroup | Yigal Nochomovitz54% | $44 → $47 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 26.92% | HC Wainwright & Co. | Matthew Caufield38% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | 23.58% | Raymond James | Gary Nachman59% | → $37 | Initiates | → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 20.24% | Piper Sandler | Joseph Catanzaro46% | $36 → $36 | Maintains | Overweight | Get Alert |
| 08/15/2024 | Buy Now | 26.92% | HC Wainwright & Co. | Matthew Caufield38% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 26.92% | HC Wainwright & Co. | Matthew Caufield38% | → $38 | Initiates | → Buy | Get Alert |
| 04/15/2024 | Buy Now | 6.88% | Leerink Partners | Marc Goodman73% | → $32 | Initiates | → Outperform | Get Alert |
| 04/15/2024 | Buy Now | — | William Blair | Tim Lugo31% | — | Initiates | → Outperform | Get Alert |
| 04/10/2024 | Buy Now | 13.56% | Citigroup | Yigal Nochomovitz54% | → $34 | Initiates | → Buy | Get Alert |
| 03/27/2024 | Buy Now | -6.48% | Piper Sandler | Joseph Catanzaro46% | → $28 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for LENZ Therapeutics (LENZ) stock?
The latest price target for LENZ Therapeutics (NASDAQ:LENZ) was reported by HC Wainwright & Co. on May 8, 2025. The analyst firm set a price target for $38.00 expecting LENZ to rise to within 12 months (a possible 26.92% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for LENZ Therapeutics (LENZ)?
The latest analyst rating for LENZ Therapeutics (NASDAQ:LENZ) was provided by HC Wainwright & Co., and LENZ Therapeutics reiterated their buy rating.
When was the last upgrade for LENZ Therapeutics (LENZ)?
There is no last upgrade for LENZ Therapeutics
When was the last downgrade for LENZ Therapeutics (LENZ)?
There is no last downgrade for LENZ Therapeutics.
When is the next analyst rating going to be posted or updated for LENZ Therapeutics (LENZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LENZ Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LENZ Therapeutics was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.
Is the Analyst Rating LENZ Therapeutics (LENZ) correct?
While ratings are subjective and will change, the latest LENZ Therapeutics (LENZ) rating was a reiterated with a price target of $38.00 to $38.00. The current price LENZ Therapeutics (LENZ) is trading at is $29.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
